tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
US Market
PTGX
Protagonist Therapeutics
Overview
Analyst Forecasts
Financials
Dividends
Technical Analysis
Options
Chart
Earnings
Ownership
Similar Stocks
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports

Protagonist Therapeutics (PTGX) Stock News & Sentiment

Compare
635 Followers
Protagonist Therapeutics: Positive VERIFY Trial Results and Promising Financial Prospects Justify Buy Rating
Premium
Ratings
Protagonist Therapeutics: Positive VERIFY Trial Results and Promising Financial Prospects Justify Buy Rating
18h ago
PTGX
Protagonist Therapeutics’ Rusfertide: A Promising Blockbuster in the Polycythemia Vera Market with Strong Buy Rating
Premium
Ratings
Protagonist Therapeutics’ Rusfertide: A Promising Blockbuster in the Polycythemia Vera Market with Strong Buy Rating
20h ago
PTGX
Protagonist Therapeutics: Buy Rating Affirmed on Rusfertide’s Phase 3 Success and Market Potential
Premium
Ratings
Protagonist Therapeutics: Buy Rating Affirmed on Rusfertide’s Phase 3 Success and Market Potential
22h ago
PTGX
Protagonist Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Results and Robust Financial Outlook
Premium
Ratings
Protagonist Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Results and Robust Financial Outlook
22h ago
PTGX
Buy Rating for Protagonist Therapeutics: Strong Potential in Rusfertide and Strategic Partnerships
Premium
Ratings
Buy Rating for Protagonist Therapeutics: Strong Potential in Rusfertide and Strategic Partnerships
4d ago
PTGX
Protagonist Therapeutics: Buy Rating Backed by Promising Trials, Strategic Partnerships, and Strong Financial Position
Premium
Ratings
Protagonist Therapeutics: Buy Rating Backed by Promising Trials, Strategic Partnerships, and Strong Financial Position
7d ago
PTGX
Protagonist Therapeutics Reports Strong 2024 Financial Results
Premium
Company Announcements
Protagonist Therapeutics Reports Strong 2024 Financial Results
7d ago
PTGX
More PTGX News >

PTGX News on the Web

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
Yahoo Finance
Neutral
Takeda and Protagonist report topline outcomes from trial of rusfertide
Clinical Trials Arena
Neutral
Protagonist Therapeutics Faces Financial Risks Amidst Growing Pharmaceutical Pricing Pressures
TipRanks News
Neutral
Investors in Protagonist Therapeutics have seen enviable returns of 397% over the past five years
Yahoo Finance
Neutral
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks News
Neutral
Protagonist Therapeutics Tops Q4 Earnings and Revenue Estimates
Yahoo Finance
Neutral
Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates
Zacks
Neutral
Protagonist Therapeutics: Q4 Earnings Snapshot
Yahoo Finance
Neutral

News Score - Last 7 Days

Neutral
PTGX
Sector Average
Media Buzz
This Week2 articles
Weekly Average3 articles
News Sentiment
This Week50%
Sector Average54%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is PTGX’s Media Buzz Sentiment?
2 articles about PTGX were published this week. In an average week, 3 articles are published.
    What is PTGX’s weekly average amount of articles?
    In an average week, 3 articles about PTGX are published.
      What is PTGX’s News Sentiment?
      50% of articles about PTGX were positive this week, compared to its sector average of 54%.
        Healthcare Stocks that are Trending in the News
        CCCCC4 Therapeutics
        JAZZJazz Pharmaceuticals
        CTECConvaTec
        CORTCorcept Therapeutics
        RCKTRocket Pharmaceuticals
        Showing the stocks with the most bullish news sentiment over the past week

        Become an Expert with TipRanks Premium

        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis
        Subscribe NowSee Plans & Pricing